Literature DB >> 35958483

Value of serum p53, PKD1, and MAP2K4 in evaluating the condition and prognosis of endometrial carcinoma.

Xiang Zhang1, Yue Huang1, Xuecheng Pang1.   

Abstract

OBJECTIVE: To analyze the p53, PKD1, and MAP2K4 expressions in serum of patients with endometrial carcinoma (EC) and their prognostic value.
METHODS: A total of 84 patients with EC who were treated in our hospital between January 2018 and January 2020 were enrolled into a research group. There were 50 healthy individuals over the same time who were included in a control group for a retrospective analysis. qRT-PCR was used for quantifying the relative levels of p53, PKD1, and MAP2K4 in the serum of the control group and the research groups (in both cancer and paracancerous tissues). The associations of p53, PKD1, and MAP2K4 with pathological features of EC were analyzed. Patients were followed up for 1 year to observe their death and analyze the associations of p53, PKD1, and MAP2K4 with prognosis of EC.
RESULTS: The patients with EC had low p53 and MAP2K4 levels and high PKD1 levels (P<0.05). The p53, MAP2K4, and PKD1 levels in serum were relevant to EC differentiation, FIGO stage, lymph node metastasis, and deep myometrial invasion (P<0.05). During the follow-up of prognosis, the serum levels of p53 and MAP2K4 in dead patients were lower than those in surviving patients. PKD1 in former patients was higher (P<0.05).
CONCLUSION: The low expressions of p53 and MAP2K4 and high expression of PKD1 in EC cases were related with disease progression. These expressions can help effectively evaluate the prognosis and survival of patients. They are of crucial research and reference significance for future diagnosis and therapy. AJTR
Copyright © 2022.

Entities:  

Keywords:  MAP2K4; PKD1; endometrial carcinoma; p53; prognosis evaluation

Year:  2022        PMID: 35958483      PMCID: PMC9360844     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  26 in total

Review 1.  Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a HuGE review and meta-analysis.

Authors:  Xin Zhou; Yang Gu; Shu-Lan Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2012

2.  Ensemble structural analyses depict the regulatory mechanism of non-phosphorylated human MAP2K4.

Authors:  Takashi Matsumoto; Akihito Yamano; Yuka Murakawa; Harumi Fukada; Masaaki Sawa; Takayoshi Kinoshita
Journal:  Biochem Biophys Res Commun       Date:  2019-10-18       Impact factor: 3.575

Review 3.  Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring.

Authors:  Myron G Best; Pieter Wesseling; Thomas Wurdinger
Journal:  Cancer Res       Date:  2018-06-19       Impact factor: 12.701

Review 4.  The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease.

Authors:  Almira Kurbegovic; Marie Trudel
Journal:  Cell Signal       Date:  2020-03-04       Impact factor: 4.315

Review 5.  Therapeutic potential of p53 reactivation in cervical cancer.

Authors:  Xiangxuan Zhao; Wei Sun; Ying Ren; Zaiming Lu
Journal:  Crit Rev Oncol Hematol       Date:  2020-11-24       Impact factor: 6.312

6.  PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Authors:  Caroline Spasojevic; Elisabetta Marangoni; Sophie Vacher; Franck Assayag; Didier Meseure; Sophie Château-Joubert; Martine Humbert; Manale Karam; Jean Marc Ricort; Christian Auclair; Marie Regairaz; Ivan Bièche
Journal:  Oncotarget       Date:  2018-05-01

Review 7.  Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.

Authors:  Martin Köbel; Brigitte M Ronnett; Naveena Singh; Robert A Soslow; C Blake Gilks; W Glenn McCluggage
Journal:  Int J Gynecol Pathol       Date:  2019-01       Impact factor: 2.762

Review 8.  Applications of RNA from circulating tumor cells.

Authors:  Sara Hassan; Tony Blick; Elizabeth D Williams; Erik W Thompson
Journal:  Front Biosci (Landmark Ed)       Date:  2020-01-01

9.  Loss of PKD1/polycystin-1 impairs lysosomal activity in a CAPN (calpain)-dependent manner.

Authors:  Lukas Peintner; Anusha Venkatraman; Astrid Waeldin; Alexis Hofherr; Tilman Busch; Alexander Voronov; Amandine Viau; E Wolfgang Kuehn; Michael Köttgen; Christoph Borner
Journal:  Autophagy       Date:  2020-10-06       Impact factor: 16.016

10.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Xavier Matias-Guiu; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio Gonzalez Martin; Sigurd Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina Sturdza; Alexandra Taylor; Anneke Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Carien L Creutzberg
Journal:  Int J Gynecol Cancer       Date:  2020-12-18       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.